Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 9/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29778323 | 1.00 | CYP2D6 (0.40) | CYP2D6CA2CA1CA7CTSK | |
| SCHEMBL31295342 | 0.93 | CYP2D6 (0.47) | CYP2D6CA2CA1CA7CTSK | |
| SCHEMBL15074960 | 0.93 | CYP2D6 (0.47) | CYP2D6CA2CA1CA7CTSK | |
| SCHEMBL25658173 | 0.88 | CA1 (0.42) | CYP2D6CA2CA1CA7CTSK | |
| SCHEMBL16285838 | 0.88 | CYP2D6 (0.39) | CYP2D6CA2CA1CA7CTSK | |
| SCHEMBL16285831 | 0.88 | CYP2D6 (0.39) | CYP2D6CA2CA1CA7CTSK | |
| SCHEMBL17294123 | 0.87 | CASP1 (0.41) | CYP2D6CA2CA1CA7CTSK | |
| SCHEMBL13633494 | 0.87 | CASP1 (0.41) | CYP2D6CA2CA1CA7CTSK | |
| SCHEMBL15071354 | 0.87 | CA1 (0.38) | CYP2D6CA2CA1CA7CTSK | |
| SCHEMBL21480838 | 0.86 | CA2 (0.35) | CYP2D6CA2CA1CA7CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618982-B2 | Heteroarylpyrrolopyridinones active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-11-17 | — | — | US | disclosed |
| US-20070142415-A1 | Heteroarylpyrrolopyridinones active as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142415-A1 | Heteroarylpyrrolopyridinones active as kinase inhibitors | MAP3K1, MAP3K19, MAP3K3 | CYP2D6 1003/4885CA2 2121/4885CA1 4431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.